Indeed, inhibitors of XPO1 (Selinexor) [56] or CDC7 (Simurosertib/TAK-931) [57] showed some single agent efficacy against a mixed LUAD/SCLC PDX model and strong combinatorial effects with EGFR inhibition in this model. This evidence concerns the gene XPO1 and small cell lung carcinoma.